LEGN

SEC filing LEGN Reports LB2501 Phase 1 Data: 100% ORR, 83% CR in NHL, No DLTs or ICANS

5h ago

SEC filing LEGN Presents LB2102 Phase 1 Data: 28.6% ORR, 78.6% DCR in Solid Tumors, CARVYKTI Shows Durable Efficacy in Multiple Myeloma

1d ago

News Legend Biotech's Cancer Drug, 'The Most Attractive Product,' Set For Growth: Analyst

14d ago

News Why Legend Biotech Stock Crushed the Market on Monday

42d ago

SEC filing LEGN Reports $555M Q4 CARVYKTI Sales, $1.9B FY Sales, 10K Patients Treated, $949M Cash, Profitable 2025

84d ago

News Mali grants ten-year renewal for Barrick’s Loulo project permit

106d ago

SEC filing LEGN Files Form 6-K, Reports on Corporate Actions and Financials for February 6, 2026

115d ago

News Legend Biotech Arcellx rise after FDA draft guidance on multiple myeloma trials

133d ago

News Arcutis Stock Is Up 100% in a Year but Here’s Why One Fund Still Sold 1 Million Shares

153d ago

News Viva Biotech's invested and incubated company, Arthrosi, has entered into an acquisition agreement with Sobi for a total transaction value of up to US$1.5 billion.

169d ago